X-108581000-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2
The NM_033380.3(COL4A5):āc.909T>Cā(p.Asp303=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000842 in 1,207,337 control chromosomes in the GnomAD database, including 17 homozygotes. There are 255 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Genomes: š 0.0012 ( 3 hom., 41 hem., cov: 22)
Exomes š: 0.00080 ( 14 hom. 214 hem. )
Consequence
COL4A5
NM_033380.3 synonymous
NM_033380.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 3.15
Genes affected
COL4A5 (HGNC:2207): (collagen type IV alpha 5 chain) This gene encodes one of the six subunits of type IV collagen, the major structural component of basement membranes. Mutations in this gene are associated with X-linked Alport syndrome, also known as hereditary nephritis. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. Alternatively spliced transcript variants have been identified for this gene. [provided by RefSeq, Aug 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -19 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.46).
BP6
Variant X-108581000-T-C is Benign according to our data. Variant chrX-108581000-T-C is described in ClinVar as [Benign]. Clinvar id is 504907.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-108581000-T-C is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=3.14 with no splicing effect.
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.00125 (139/111536) while in subpopulation AMR AF= 0.0129 (134/10426). AF 95% confidence interval is 0.0111. There are 3 homozygotes in gnomad4. There are 41 alleles in male gnomad4 subpopulation. Median coverage is 22. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 3 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL4A5 | NM_033380.3 | c.909T>C | p.Asp303= | synonymous_variant | 16/53 | ENST00000328300.11 | NP_203699.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL4A5 | ENST00000328300.11 | c.909T>C | p.Asp303= | synonymous_variant | 16/53 | 1 | NM_033380.3 | ENSP00000331902 | ||
COL4A5 | ENST00000361603.7 | c.909T>C | p.Asp303= | synonymous_variant | 16/51 | 2 | ENSP00000354505 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00125 AC: 139AN: 111485Hom.: 3 Cov.: 22 AF XY: 0.00122 AC XY: 41AN XY: 33679
GnomAD3 genomes
AF:
AC:
139
AN:
111485
Hom.:
Cov.:
22
AF XY:
AC XY:
41
AN XY:
33679
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00379 AC: 694AN: 183338Hom.: 8 AF XY: 0.00251 AC XY: 170AN XY: 67818
GnomAD3 exomes
AF:
AC:
694
AN:
183338
Hom.:
AF XY:
AC XY:
170
AN XY:
67818
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000801 AC: 878AN: 1095801Hom.: 14 Cov.: 29 AF XY: 0.000592 AC XY: 214AN XY: 361365
GnomAD4 exome
AF:
AC:
878
AN:
1095801
Hom.:
Cov.:
29
AF XY:
AC XY:
214
AN XY:
361365
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00125 AC: 139AN: 111536Hom.: 3 Cov.: 22 AF XY: 0.00122 AC XY: 41AN XY: 33740
GnomAD4 genome
AF:
AC:
139
AN:
111536
Hom.:
Cov.:
22
AF XY:
AC XY:
41
AN XY:
33740
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:4
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 05, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Nov 19, 2018 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 21, 2016 | p.Asp303Asp in exon 16 of COL4A5: This variant is not expected to have clinical significance because it does not alter an amino acid residue, is not located wit hin the splice consensus sequence, and has been identified in 2.64% (245/9283) o f Latino chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broa dinstitute.org; dbSNP rs144586397). - |
X-linked Alport syndrome Benign:1
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Dec 03, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at